Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Luye Pharma Group Ltd. It details authorized share capital, issued shares, treasury shares, public float sufficiency, and convertible bonds. The document is structured as a regulatory compliance report under HKEX Listing Rules Chapter 19B, providing detailed monthly updates on share capital and securities movements. It is not an annual or interim financial report, earnings release, or management discussion. It is also not a proxy statement, AGM material, or legal proceeding. The document is a regulatory filing specifically reporting share capital and securities movements as required by the exchange rules. Given the detailed nature and regulatory context, this fits best under Regulatory Filings (RNS). The document length and content confirm it is not a mere announcement but a substantive regulatory report. Confidence is high due to clear regulatory references and detailed securities data.
2026-05-07 English
Environmental, Social and Governance Report 2025
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report 2025' for Luye Pharma Group Ltd. It contains detailed sections on ESG governance framework, risk management, environmental protection, social performance, and awards related to ESG achievements. The report covers the full year 2025 and is prepared in accordance with the ESG Code issued by the Hong Kong Stock Exchange and GRI Standards. It is a comprehensive report focusing on environmental, social, and governance factors rather than financial performance or regulatory filings. Therefore, it fits the category of Environmental & Social Information (ESG) report.
2026-04-29 English
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Luye Pharma Group Ltd. regarding the enrollment of the first subject in a U.S. pharmacokinetic bridging clinical trial for a new drug LY03015. It discusses the drug's mechanism, clinical trial design, and the company's strategic focus on CNS therapeutic areas. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an announcement of a clinical trial milestone, not a financial report, regulatory filing, or management update. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category as it informs the market about a significant development related to the company's drug pipeline. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-20 English
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS
Regulatory Filings Classification · 85% confidence The document is a “Voluntary Announcement” filed on the Hong Kong Exchange, providing an operational update on a drug’s clinical trial enrollment. It does not present financial results, governance changes, dividends, or any of the other narrowly defined categories. Instead, it is a general regulatory announcement to shareholders and the market. Therefore, it falls into the fallback category for miscellaneous regulatory filings (RNS).
2026-04-15 English
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020
Regulatory Filings Classification · 82% confidence The document is a voluntary corporate announcement published on the Hong Kong stock exchange regarding the enrollment of the first subject in a Phase II clinical trial for an innovative drug. It does not constitute a financial report (10-K, IR, ER), management change (MANG), capital action (CAP, SHA, POS), M&A (TAR), dividend notice (DIV), AGM materials (AGM-R), or any specialized category. Therefore it falls under a general regulatory announcement category (RNS).
2026-04-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 90% confidence The document is a regulatory monthly return (Form FF301) submitted to the Hong Kong Exchange under Chapter 19B of the Listing Rules, detailing authorised/registered share capital, issued shares and movements in convertible bonds. It is not an earnings release, annual report, AGM material, or management discussion, nor a proxy or dividend notice. It is a compliance filing under the exchange’s listing rules, and does not announce a specific report publication or a single share issue event. Therefore it falls under the general Regulatory Filings category (RNS).
2026-04-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.